These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19726184)

  • 1. Discovery of the imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepine scaffold as a novel, potent and selective GABA(A) alpha5 inverse agonist series.
    Achermann G; Ballard TM; Blasco F; Broutin PE; Büttelmann B; Fischer H; Graf M; Hernandez MC; Hilty P; Knoflach F; Koblet A; Knust H; Kurt A; Martin JR; Masciadri R; Porter RH; Stadler H; Thomas AW; Trube G; Wichmann J
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5746-52. PubMed ID: 19726184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepines as potent and highly selective GABAA alpha5 inverse agonists with potential for the treatment of cognitive dysfunction.
    Buettelmann B; Ballard TM; Gasser R; Fischer H; Hernandez MC; Knoflach F; Knust H; Stadler H; Thomas AW; Trube G
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5958-61. PubMed ID: 19740657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA alpha5 inverse agonists for the treatment of cognitive dysfunction.
    Knust H; Achermann G; Ballard T; Buettelmann B; Gasser R; Fischer H; Hernandez MC; Knoflach F; Koblet A; Stadler H; Thomas AW; Trube G; Waldmeier P
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5940-4. PubMed ID: 19762240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of 3-heterocyclyl-7,8,9,10-tetrahydro-(7,10-ethano)-1,2,4-triazolo[3,4-a]phthalazines and analogues as subtype-selective inverse agonists for the GABA(A)alpha5 benzodiazepine binding site.
    Street LJ; Sternfeld F; Jelley RA; Reeve AJ; Carling RW; Moore KW; McKernan RM; Sohal B; Cook S; Pike A; Dawson GR; Bromidge FA; Wafford KA; Seabrook GR; Thompson SA; Marshall G; Pillai GV; Castro JL; Atack JR; MacLeod AM
    J Med Chem; 2004 Jul; 47(14):3642-57. PubMed ID: 15214791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a novel, selective GABA(A) alpha5 receptor inverse agonist which enhances cognition.
    Chambers MS; Atack JR; Broughton HB; Collinson N; Cook S; Dawson GR; Hobbs SC; Marshall G; Maubach KA; Pillai GV; Reeve AJ; MacLeod AM
    J Med Chem; 2003 May; 46(11):2227-40. PubMed ID: 12747794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GABAA receptor subtype-selective modulators. II. α5-selective inverse agonists for cognition enhancement.
    Atack JR
    Curr Top Med Chem; 2011; 11(9):1203-14. PubMed ID: 21050171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of functionally selective 7,8,9,10-tetrahydro-7,10-ethano-1,2,4-triazolo[3,4-a]phthalazines as GABA A receptor agonists at the alpha3 subunit.
    Russell MG; Carling RW; Atack JR; Bromidge FA; Cook SM; Hunt P; Isted C; Lucas M; McKernan RM; Mitchinson A; Moore KW; Narquizian R; Macaulay AJ; Thomas D; Thompson SA; Wafford KA; Castro JL
    J Med Chem; 2005 Mar; 48(5):1367-83. PubMed ID: 15743180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3-phenyl-6-(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-a]phthalazines and analogues: high-affinity gamma-aminobutyric acid-A benzodiazepine receptor ligands with alpha 2, alpha 3, and alpha 5-subtype binding selectivity over alpha 1.
    Carling RW; Moore KW; Street LJ; Wild D; Isted C; Leeson PD; Thomas S; O'Connor D; McKernan RM; Quirk K; Cook SM; Atack JR; Wafford KA; Thompson SA; Dawson GR; Ferris P; Castro JL
    J Med Chem; 2004 Mar; 47(7):1807-22. PubMed ID: 15027873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The proconvulsant effects of the GABAA alpha5 subtype-selective compound RY-080 may not be alpha5-mediated.
    Atack JR; Bayley PJ; Fletcher SR; McKernan RM; Wafford KA; Dawson GR
    Eur J Pharmacol; 2006 Oct; 548(1-3):77-82. PubMed ID: 16962577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective, orally active gamma-aminobutyric acidA alpha5 receptor inverse agonists as cognition enhancers.
    Sternfeld F; Carling RW; Jelley RA; Ladduwahetty T; Merchant KJ; Moore KW; Reeve AJ; Street LJ; O'Connor D; Sohal B; Atack JR; Cook S; Seabrook G; Wafford K; Tattersall FD; Collinson N; Dawson GR; Castro JL; MacLeod AM
    J Med Chem; 2004 Apr; 47(9):2176-9. PubMed ID: 15084116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine: a functionally selective gamma-aminobutyric acid(A) (GABA(A)) alpha2/alpha3-subtype selective agonist that exhibits potent anxiolytic activity but is not sedating in animal models.
    Carling RW; Madin A; Guiblin A; Russell MG; Moore KW; Mitchinson A; Sohal B; Pike A; Cook SM; Ragan IC; McKernan RM; Quirk K; Ferris P; Marshall G; Thompson SA; Wafford KA; Dawson GR; Atack JR; Harrison T; Castro JL; Street LJ
    J Med Chem; 2005 Nov; 48(23):7089-92. PubMed ID: 16279764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New 1,5-benzodiazepine compounds: activity at native GABA(A) receptors.
    Gatta E; Cupello A; Di Braccio M; Grossi G; Ferruzzi R; Roma G; Robello M
    Neuroscience; 2010 Mar; 166(3):917-23. PubMed ID: 20096335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A structure-based QSAR and docking study on imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4,]benzodiazepines as Selective GABA(A) α5 inverse agonists.
    Gharaghani S; Khayamian T; Keshavarz F
    Chem Biol Drug Des; 2011 Oct; 78(4):612-21. PubMed ID: 21756285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel 3-iodo-8-ethoxypyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide as promising lead for design of alpha5-inverse agonist useful tools for therapy of mnemonic damage.
    Guerrini G; Ciciani G; Cambi G; Bruni F; Selleri S; Besnard F; Montali M; Martini C; Ghelardini C; Galeotti N; Costanzo A
    Bioorg Med Chem; 2007 Apr; 15(7):2573-86. PubMed ID: 17306981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability.
    Johnson PS; Ryckmans T; Bryans J; Beal DM; Dack KN; Feeder N; Harrison A; Lewis M; Mason HJ; Mills J; Newman J; Pasquinet C; Rawson DJ; Roberts LR; Russell R; Spark D; Stobie A; Underwood TJ; Ward R; Wheeler S
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5684-7. PubMed ID: 21885275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. γ-Aminobutyric acid type A (GABA(A)) receptor subtype inverse agonists as therapeutic agents in cognition.
    Gabriella G; Giovanna C
    Methods Enzymol; 2010; 485():197-211. PubMed ID: 21050918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tricyclic heteroaromatic systems. 2-Phenyl-1,2,4-triazolo[1,5-c][1,3]benzoxazin-5-one: a novel benzodiazepine receptor ligand.
    Catarzi D; Cecchi L; Colotta V; Filacchioni ; Martini C; Giusti L; Lucacchini A; Valle G
    Farmaco; 1994 Feb; 49(2):89-92. PubMed ID: 8003185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel GABA(A) alpha 5 receptor inhibitor with therapeutic potential.
    Ling I; Mihalik B; Etherington LA; Kapus G; Pálvölgyi A; Gigler G; Kertész S; Gaál A; Pallagi K; Kiricsi P; Szabó É; Szénási G; Papp L; Hársing LG; Lévay G; Spedding M; Lambert JJ; Belelli D; Barkóczy J; Volk B; Simig G; Gacsályi I; Antoni FA
    Eur J Pharmacol; 2015 Oct; 764():497-507. PubMed ID: 26169564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High affinity central benzodiazepine receptor ligands: synthesis and biological evaluation of a series of phenyltriazolobenzotriazindione derivatives.
    Primofiore G; Da Settimo F; Taliani S; Salerno S; Novellino E; Greco G; Cosimelli B; Besnard F; Costa B; Montali M; Martini C
    J Med Chem; 2005 Apr; 48(8):2936-43. PubMed ID: 15828832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating enhanced GABAergic inhibition in Down syndrome: use of GABA α5-selective inverse agonists.
    Martínez-Cué C; Delatour B; Potier MC
    Neurosci Biobehav Rev; 2014 Oct; 46 Pt 2():218-27. PubMed ID: 24412222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.